Ultrahypofractionated Radiotherapy for Localized Prostate Cancer: A Review of Evidence and Future Perspectives

Research presented in a recent narrative review has shed light on the effectiveness of ultrahypofractionated radiotherapy in treating localized prostate cancer. The study compared single-session and two-session approaches in Stereotactic Body Radiation Therapy (SBRT) and high-dose-rate (HDR) brachytherapy, highlighting the potential benefits of these ultra-hypofractionated strategies in delivering high-precision ablative doses while minimizing exposure to normal tissues.

Key Takeaways:

• Single-session SBRT regimens with fewer than five fractions show tumor control comparable to conventional treatments, offering reduced treatment burden and increased convenience.
• Two-fraction regimens, especially in HDR brachytherapy, are widely used and may better preserve normal tissues and reduce toxicity.
• Advanced imaging, real-time motion management, and adaptive planning improve treatment accuracy, making two-session approaches safe and effective in the short to intermediate term.
• Long-term data for single-session SBRT remain limited, and further research is needed to refine ultra-hypofractionated radiotherapy protocols for prostate cancer.
• Tailoring treatment based on patient factors, tumor characteristics, and institutional capabilities is essential for optimizing outcomes with ultra-hypofractionated radiotherapy.
• The review emphasizes the importance of considering patient individuality and institutional capabilities when selecting treatment approaches.

Statistics:

• The study highlights that single-dose outcomes with SBRT are often suboptimal, with limited long-term data available.
• Two-fraction regimens in HDR brachytherapy demonstrate improved preservation of normal tissues and reduced toxicity compared to single-session SBRT.
• The review emphasizes the need for further research to refine ultra-hypofractionated radiotherapy protocols for prostate cancer, including the development of new imaging techniques and motion management strategies.

Sources:

• "Ultrahypofractionated radiotherapy in one or two sessions for localized prostate cancer: a review of the evidence and future perspectives." Clinical and Translational Oncology, 2025.
• NewsRx. Reports on Prostate Cancer from Department of Radiation Oncology Provide New Insights (Ultrahypofractionated radiotherapy in one or two sessions for localized prostate cancer: a review of the evidence and future perspectives). Health & Medicine Week. September 26, 2025; p 5316.